Internal Reference Number: FOI_7068
Date Request Received: 13/03/2023 00:00:00
Date Request Replied To: 03/04/2023 00:00:00
This response was sent via: By Email
Request Summary: Oesophageal and Gastric cancer
Request Category: Companies
Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
Answer To Question 1: <5 patients treated with FOLFOX <5 patients treated with other systemic anticancer therapy <5 patients treated with palliative care only 0 patients for the rest of the treatment options | |
Question Number 2: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Nivolumab monotherapy • Nivolumab and Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
Answer To Question 2: <5 patients treated with Platinum and Fluoropyrimidene based combination treatments <5 patients treated with Pembrolizumab in combination with Platinum <5 patients treated with other systemic anticancer therapy <5 patients treated with palliative care only 0 patients for the rest of the treatment options | |
Question Number 3: Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part. | |
Answer To Question 3: Add- Aspirin 77 participants | |
Question Number 4: Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part. | |
Answer To Question 4: No trials in this area | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.